Evaluating MDD Treatment Attributes

EP: 1.Unmet Needs in Treatment of MDD

EP: 2.MDD Treatment Landscape

EP: 3.Potential Consequences of Recurrent or Poorly Controlled MDD

EP: 4.Burden of Treatment Failure in MDD

EP: 5.Importance of Early Effective Treatment of MDD

Now Viewing

EP: 6.Evaluating MDD Treatment Attributes

EP: 7.Considerations for Newly Launched MDD Treatments

EP: 8.Healthcare Disparities Within Major Depressive Disorder

EP: 9.MDD Treatment Disparities Across Patient Populations

EP: 10.Social Determinants of Health in MDD

EP: 11.Impact of COVID-19 on Demand for Mental Health Services

EP: 12.Health Care Disparities Within Major Depressive Disorder (MDD)

EP: 13.MDD Treatment Disparities Across Patient Populations: Part 2

EP: 14.Social Determinants of Health in MDD: Part 2

EP: 15.Population Health Approach in MDD

EP: 16.Factors Affecting MDD Treatment Adherence

EP: 17.Supporting Adherence for Patients with MDD

EP: 18.Aligning MDD Treatment Goals for Payers and Patients

EP: 19.The Impact of Early Effective Treatment in MDD

EP: 20.Key Contributors to Long-term Outcomes for Patients With MDD

H. Eric Cannon, PharmD, FAMCP: The attributes that we value most include a product that has early onset of benefit for the patient. The quicker that onset can happen, the better. We’ve talked about that already. But we also want to minimize the impact of adverse effects, everything from sexual dysfunction to fatigue to dry mouth or something else that’s bothersome to the patient. All those things need to be factored in. In some cases, the treatment may be working but we’ve increased a certain level of anxiety with the patient. Finding that right treatment and minimizing the adverse effects is critical.

Michael Rothrock, MBA, MHA: We’ve already mentioned many times that onset of action is one of the major factors that’s going to drive interest in getting effective therapies for patients with MDD [major depressive disorder]. But as Dr Cannon mentioned, the safety and tolerability are big. Weight gain is another thing I would throw into that mix. We also want to make sure there’s durability of benefit. We want to see patients respond and stay responding. Or do they have to titrate? Is there a reason they discontinue? We want to minimize gaps in care. We want to have consistency. All of that is going to be important.

Another thing that’s important is a different mechanism of action. We’re pretty saturated with SSRIs [selective serotonin reuptake inhibitors] and SNRIs [serotonin-norepinephrine reuptake inhibitors]. We want something new, novel, and different for those who have previously tried and failed generic options.

Transcript edited for clarity.